Aktis Oncology
A biotech company developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors.
The company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy.
In May 2024, Aktis announced a multi-target discovery collaboration agreement with Eli Lilly to generate anticancer radiopharmaceuticals using Aktis' novel miniprotein technology platform. Under the deal, Aktis will be responsible for program discovery through initial human imaging studies, and Lilly will beresponsible for worldwide clinical development and commercialization from Phase I onward.
Latest Aktis Oncology News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze